Drugs & Targets EC approves Sarclisa in combination with VRd for transplant-eligible newly diagnosed MM August 01, 2025Vol.51 No.30
Conversation with The Cancer Letter Will MCD tests revolutionize cancer screening? NCI begins enrollment in Vanguard “feasibility” trial to start finding out July 25, 2025Vol.51 No.29By Sara Willa Ernst, Jacquelyn Cobb and Paul Goldberg
Conversation with The Cancer Letter Robert Winn: If Medicaid gets massive cuts or goes away, where will these patients get care? July 25, 2025Vol.51 No.29By Sara Willa Ernst
Oncologist biotech entrepreneur George Tidmarsh joins FDA as CDER directorHis appointment came out of “proximity” to Makary and Bhattacharya July 25, 2025Vol.51 No.29By Claire Marie Porter
Cancer Policy FY25 paylines drop to 4th percentile—a historic low—as NCI braces for Trump’s FY26 budget cuts July 25, 2025Vol.51 No.29By Jacquelyn Cobb
Cancer Policy Right-wing provocateur Laura Loomer comes for FDA’s Vinay Prasad July 25, 2025Vol.51 No.29By Claire Marie Porter
Cancer Policy The effects of NIH, FDA cuts will be felt for decades, CBO report estimates July 25, 2025Vol.51 No.29By Paul Goldberg
Cancer Policy COI statement prohibits “unseemly advocacy,” “undue influence” by industry rep on ODAC July 25, 2025Vol.51 No.29By Paul Goldberg
Cancer Policy Columbia settles with Trump, agreeing to a $200M fine, as Harvard fights on July 25, 2025Vol.51 No.29By Claire Marie Porter and Jacquelyn Cobb
